A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer
Phase 1 Withdrawn
A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer
Phase 1 Withdrawn
Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer
Phase 1 Withdrawn
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
Phase 1 Withdrawn
Study of OB-002 in Patients With Refractory Metastatic Cancer
Phase 1 Withdrawn
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
Phase 1 Withdrawn
Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer
Phase 1 Withdrawn
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Withdrawn
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
Phase 1 Withdrawn
Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial
Phase 1 Withdrawn
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
Phase 1 Withdrawn
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Phase 1 Withdrawn
Vaccine Response With NT-I7
Phase 1 Withdrawn
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
Phase 1 Withdrawn
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Phase 1 Withdrawn
Implantable Microdevice for TNBC - Pilot Study
Phase 1 Withdrawn
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
Phase 1 Withdrawn
LABC
Phase 1 Withdrawn
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors
Phase 1 Withdrawn
AIPAC-002
Phase 1 Withdrawn
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Phase 1 Withdrawn
SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer
Phase 1 Withdrawn
Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
Phase 1 Withdrawn
CS-1000
Phase 1 Withdrawn
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
Phase 1 Withdrawn
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Phase 1 Withdrawn
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Phase 1 Withdrawn
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
Phase 1 Withdrawn
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
Phase 1 Withdrawn
Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer
Phase 1 Withdrawn
LCCC1820
Phase 1 Withdrawn
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Phase 1 Withdrawn
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
Phase 1 Withdrawn
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
Phase 1 Withdrawn
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Phase 1 Withdrawn
Imaging With [11C]Martinostat in Breast Cancer
Phase 1 Withdrawn
rVV-740CTA
Phase 1 Withdrawn
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Phase 1 Withdrawn
IMGN853
Phase 1 Withdrawn
L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer
Phase 1 Withdrawn
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Phase 1 Withdrawn
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
Phase 1 Withdrawn
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Phase 1 Withdrawn
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Withdrawn
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase 1 Withdrawn
Reirradiation With Concurrent Paclitaxel for Breast Cancer
Phase 1 Withdrawn
Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
Phase 1 Withdrawn
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
Phase 1 Withdrawn
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
Phase 1 Withdrawn
CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery
Phase 1 Withdrawn